Virus Like Particles
-
Upload
mohammad-abrar-gayath -
Category
Education
-
view
21 -
download
1
Transcript of Virus Like Particles
![Page 1: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/1.jpg)
VIRUS LIKE PARTICLES
Abrar Gayas VB/2011/1075
3rd YEAR
![Page 2: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/2.jpg)
WHAT? VLPs are formed by structural viral
proteins which have an inherent property for self-assembly, and mimic the morphology of the pathogen.
In contrast to live viruses, VLPs are non-infective and non-replicating, since they are essentially devoid of infectious genetic material.
![Page 3: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/3.jpg)
![Page 4: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/4.jpg)
![Page 5: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/5.jpg)
VLPs are often used in studies to identify protein components required for viral assembly.
VLPs are useful tools for the development of vaccines.
Protein Delivery
WHY TO STUDY VLPs
![Page 6: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/6.jpg)
As Vaccines DEVELOPMENT
Over recent years, advances in recombinant DNA technologies and genetic engineering have led to the development of subunit vaccines (SUVs)
SUVs are based on specific components of pathogens, often located on their surface. Therefore, SUVs are considered safer than full pathogen-based inactivated or live attenuated vaccines
Virus-like particles (VLPs) represent a major advancement in the development of SUVs with enhanced immunogenicity.
![Page 7: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/7.jpg)
HOW???? VLPs display antigenic epitopes in
the correct conformation and in a highly repetitive manner, leading to cross-linking of B cell immunoglobulin receptors and B cell activation
As exogenous antigens, VLPs are efficiently taken up by professional antigen presenting cells, particularly dendritic cells (DCs),followed by antigen processing and presentation by MHC class II molecules
![Page 8: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/8.jpg)
DC activation and maturation through up-regulation of co stimulatory molecules and cytokine production, and stimulation of CD4+T helper cells, leading to the induction of strong humoral and cellular immune responses
Similar to native viruses, VLPs are processed in the cytosol of DCs and are presented by MHC class I molecules to cytotoxic CD8+T cells by the cross-presentation mechanism, inducing potent cytotoxic immune response
![Page 9: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/9.jpg)
A number of VLP-based vaccine candidates, including GSK’s anti-malaria vaccine RTS,S, are in clinical development while many others, targeting pathogens such as influenza virus, rotavirus and human immunodeficiency virus are undergoing pre-clinical evaluation .
![Page 10: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/10.jpg)
i
INFECTIOUS INFLUENZA VIRUS
![Page 11: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/11.jpg)
To date, VLPs, non-enveloped and enveloped, have been produced for a number of targets using mammalian, plant , insect , yeast or bacterial cells and cell-free platforms
![Page 12: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/12.jpg)
VLPs formed in yeast or insect larvae are purified after breaking the cells and incorporated with fish food pellets
Alternatively, purified VLPs are encapsulated and mixed into feed for oral delivery
![Page 13: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/13.jpg)
![Page 14: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/14.jpg)
TYPES Non-enveloped VLPs are typically composed of one or
more components of a pathogen with the ability to self-assemble into particles and do not include any host components (Fig. 1A).
This approach has been used to develop vaccines against such pathogens as HPV and RV . Non-enveloped VLPs continue to be explored as a preferred approach for developing SUVs against a number of pathogens, including canine, mink and porcine parvoviruses using VP2 protein expressed in insect cells
In summary, non-enveloped VLPs can consist of a single or multiple components of a target pathogen or a single or multiple vaccine target antigens displayed on the VLP surface as afusion to a heterologous viral protein with the ability to self-assemble
![Page 15: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/15.jpg)
Enveloped VLPs are relatively complex structures consisting of the host cell membrane (an envelope) with integrated target anti-gens displayed on the outer surface
Enveloped VLPs provide a higher degree of flexibility for integration of more antigens from the same or heterologous pathogens The most prominent examples of enveloped VLPs are VLPs engineered to express vaccine target antigens from influenza viruses retroviruses and hepatitis C virus (HCV)
![Page 16: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/16.jpg)
Production of enveloped VLPs requires co-expression of several structural viral proteins, their assembly into particles, incorporation into host membranes and release of particles (budding) from the cell membraneFor example, a successful assembly and bud-ding of influenza A/Udorn/72 (H3N2) VLPs have been achieved by co-expressing four structural proteins (hemagglutinin [HA], neuraminidase [NA], matrix protein M1 and ion channel protein M2) of the virus. In conclusion, enveloped VLPs represent complex structures consisting of multiple components of target pathogens and host membrane components and resemble the pathogen
![Page 17: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/17.jpg)
As Protein Delivery: Cell Culture Transfection
Using Three Components:
1. Protein(Thereupetic Drug) 2. Structural Protein Isolated From Virus
3. Surface Proteins Dotted With Glycoproteins
Used In Prostate Cancer
![Page 18: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/18.jpg)
Thank you
![Page 19: Virus Like Particles](https://reader035.fdocuments.us/reader035/viewer/2022062502/58a11d3d1a28abb91b8b4d6f/html5/thumbnails/19.jpg)